重症急性辐射损伤治疗新策略——造血因子早期干预治疗

无论是军事或恐怖行动的核爆炸还是民用核设施的事故性爆炸,均可致大规模人群受到不同程度的电离辐射照射,产生大量的重症急性辐射损伤（SARI）患者。过去二十多年,对SARI患者的救治大多采用造血干细胞移植,然而数十例辐射事故患者接受移植后的结果表明其治疗效果并不理想,至今无一长期活存。实验研究结果显示,7.0或10.0 Gy 60Coγ射线照射猴在照射后24 h内给予大剂量重组人粒细胞集落刺激因子（rhG-CSF）或重组人血小板生成素（rhTPO）治疗可明显促进受照射动物造血恢复、缩短抗感染和抗出血治疗时间、增加照射动物活存率。对于受5.0～10.0Gy照射所致的SARI患者的临床治疗,尽早使用rhG-CSF或（和）rhTPO是目前首选的治疗策略。

Current treatment strategies for severe acute radiation injury:early intervention by hematopoietic growth factors

Nuclear detonation through either military,terrorist action and accidental explosion of civil nuclear facility would most likely lead to a mass-casualty scenario involving victims with varying degrees of exposure to ionizing radiation and induce a large number of patients with severe acute radiation injury(SARI).In more than twenty years,many of SARI patients were treated with hematopoietic stem cell transplantation(HSCT),but the effect was not ideal.Dozens of the patients underwent HSCT did not have a long...